Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

January 6, 2023

Primary Completion Date

August 31, 2025

Study Completion Date

September 30, 2028

Conditions
Autosomal Dominant Hypocalcemia (ADH)
Interventions
DRUG

Encaleret

Administered as film-coated tablet for oral use

DIETARY_SUPPLEMENT

Standard of Care

Calcium supplements and/or active Vitamin D (calcitriol, alfacalcidol, falecalcitriol, etc.)

Trial Locations (25)

2065

Royal North Shore Hospital, Saint Leonards

4029

Royal Brisbane and Women's Hospital, Herston

8200

Aarhus University Hospital, Aarhus

10032

Columbia University Irving Medical Center, New York

19104

The Children's Hospital of Philadelphia, Philadelphia

20132

IRCCS Ospedale San Raffaele, Milan

20892

NIH, Bethesda

27834

Physicians East, Greenville

43203

Ohio State University Medical Center, Columbus

46202

Indiana University Health University Hospital, Indianapolis

55905

Mayo Clinic - Rochester, Rochester

56124

University Hospital of Pisa, Pisa

69003

Hôpital Edouard Herriot - HCL, Lyon

77030

Houston Methodist Hospital, Houston

80045

Children's Hospital Colorado, Aurora

94270

CHU Bicetre, Le Kremlin-Bicêtre

94609

UCSF Benioff Children's Hospital, Oakland, Oakland

02114

Massachusetts General Hospital, Boston

L6M 1M1

Bone Research & Education Centre, Oakville

128 08

Vseobecna fakultni nemocnice v Praze, New Town

00128

Fondazione Policlinico Universitario Campus Bio-Medico, Roma

113-8655

The University of Tokyo Hospital, Tokyo

3015 AA

Eramus MC, Rotterdam

NE7 7DN

Freeman Hospital, Newcastle upon Tyne

NR4 7UY

Norfolk and Norwich University Hospital, Norwich

All Listed Sponsors
lead

Calcilytix Therapeutics, Inc., a BridgeBio company

INDUSTRY

NCT05680818 - Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1 | Biotech Hunter | Biotech Hunter